Switch theme
Sign up to access all valuation multiples
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
2016
800
LTM Revenue $65.1M
LTM EBITDA -$483M
$1.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Recursion Pharmaceuticals has a last 12-month revenue of $65.1M and a last 12-month EBITDA of -$483M.
In the most recent fiscal year, Recursion Pharmaceuticals achieved revenue of $58.5M and an EBITDA of -$427M.
Recursion Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Recursion Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $43.9M | $58.5M | XXX | XXX | XXX |
| Gross Profit | -$8.6M | $1.3M | XXX | XXX | XXX |
| Gross Margin | -20% | 2% | XXX | XXX | XXX |
| EBITDA | -$308M | -$427M | XXX | XXX | XXX |
| EBITDA Margin | -701% | -730% | XXX | XXX | XXX |
| Net Profit | -$239M | -$328M | XXX | XXX | XXX |
| Net Margin | -546% | -561% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Recursion Pharmaceuticals's stock price is $6.
Recursion Pharmaceuticals has current market cap of $2.2B, and EV of $1.7B.
See Recursion Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.7B | $2.2B | XXX | XXX | XXX | XXX | $-1.67 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Recursion Pharmaceuticals has market cap of $2.2B and EV of $1.7B.
Recursion Pharmaceuticals's trades at 26.6x LTM EV/Revenue multiple, and -3.6x LTM EBITDA.
Analysts estimate Recursion Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Recursion Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.7B | XXX | XXX | XXX |
| EV/Revenue | 29.6x | XXX | XXX | XXX |
| EV/EBITDA | -4.1x | XXX | XXX | XXX |
| P/E | -4.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpRecursion Pharmaceuticals's NTM/LTM revenue growth is 36%
Recursion Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Recursion Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Recursion Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Recursion Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 33% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -730% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 39% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -694% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 305% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 538% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 842% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Recursion Pharmaceuticals acquired XXX companies to date.
Last acquisition by Recursion Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Recursion Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Recursion Pharmaceuticals founded? | Recursion Pharmaceuticals was founded in 2016. |
| Where is Recursion Pharmaceuticals headquartered? | Recursion Pharmaceuticals is headquartered in United States of America. |
| How many employees does Recursion Pharmaceuticals have? | As of today, Recursion Pharmaceuticals has 800 employees. |
| Who is the CEO of Recursion Pharmaceuticals? | Recursion Pharmaceuticals's CEO is Dr. Christopher Gibson, PhD. |
| Is Recursion Pharmaceuticals publicy listed? | Yes, Recursion Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Recursion Pharmaceuticals? | Recursion Pharmaceuticals trades under RXRX ticker. |
| When did Recursion Pharmaceuticals go public? | Recursion Pharmaceuticals went public in 2021. |
| Who are competitors of Recursion Pharmaceuticals? | Similar companies to Recursion Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Recursion Pharmaceuticals? | Recursion Pharmaceuticals's current market cap is $2.2B |
| What is the current revenue of Recursion Pharmaceuticals? | Recursion Pharmaceuticals's last 12-month revenue is $65.1M. |
| What is the current EBITDA of Recursion Pharmaceuticals? | Recursion Pharmaceuticals's last 12-month EBITDA is -$483M. |
| What is the current EV/Revenue multiple of Recursion Pharmaceuticals? | Current revenue multiple of Recursion Pharmaceuticals is 26.6x. |
| What is the current EV/EBITDA multiple of Recursion Pharmaceuticals? | Current EBITDA multiple of Recursion Pharmaceuticals is -3.6x. |
| What is the current revenue growth of Recursion Pharmaceuticals? | Recursion Pharmaceuticals revenue growth between 2023 and 2024 was 33%. |
| Is Recursion Pharmaceuticals profitable? | Yes, Recursion Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
